Notid SIGNED
Novel Target for Treatment of Chronic Inflammatory Diseases
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Notid project word cloud
Explore the words cloud of the Notid project. It provides you a very rough idea of what is the project "Notid" about.
Project "Notid" data sheet
The following table provides information about the project.
| Coordinator |
LIPUM AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Project website | http://www.lipumpharma.com |
| Total cost | 3˙170˙983 € |
| EC max contribution | 2˙219˙688 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-11-01 to 2020-07-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
Lipum AB has discovered a novel target protein for treatment of chronic inflammatory diseases. We are now developing a biological drug that will inhibit the target molecule. We propose an entirely new therapeutic mode of action as an alternative to current therapeutics that do not provide adequate response in as much as 1/3 of patients. Our research and preclinical results indicate that our approach can be applied for treatment of an array of autoimmune and autoinflammatory conditions, and that the suppression of the patient immune system can be avoided, which otherwise is a common negative side effect limiting treatment options. Currently, Lipum is focused on delivering a humanised candidate drug. Our aim is to to reach a drug development phase where toxicology and safety tests can be started and establish collaborations needed to proceed with the clinical studies. Within the lifecycle of this project, Lipum will focus on providing preclinical evidence, securing IP and reaching out to partners interested in exploitation of our approach for the treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. These are chronic and debilitating conditions that affect around 1% of adult population (RA) or thousands of children (JIA) worldwide. Both RA and JIA are important cause of disability and generate high costs of healthcare and lost productivityLipum AB is a Swedish SME founded in 2010 with the aim to bring to the market a new biological drug for chronic inflammatory diseases. An effective and safe alternative has been long expected by the millions of patients that struggle with chronic and debilitating conditions like Rheumatoid arthritis (RA), Psoriatic Arthritis (PsA), or Inflammatory Bowel Disease (IBD), and by the rheumatology opinion leaders that have been highlighting the unmet clinical need in this domain. Apart from the patients’ well-being and quality of life, chronic inflammatory diseases incur high social costs of healthcare and lost productivity.
Deliverables
| Project website and social media channels | Websites, patent fillings, videos etc. | 2020-02-12 12:05:25 |
Take a look to the deliverables list in detail: detailed list of Notid deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOTID" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NOTID" are provided by the European Opendata Portal: CORDIS opendata.